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Triazole fungicides are used broadly for the control of infectious diseases of both humans
and plants. The surge in resistance to triazoles among pathogenic populations is an emer-
gent issue both in agriculture and medicine. The non-rational use of fungicides with
site-speciﬁc modes of action, such as the triazoles, may increase the risk of antifungal
resistance development. In the medical ﬁeld, the surge of resistant fungal isolates has been
related to the intensive and recurrent therapeutic use of a limited number of triazoles for
the  treatment and prophylaxis of many mycoses. Similarities in the mode of action of tri-
azole  fungicides used in these two ﬁelds may lead to cross-resistance, thus expanding the
spectrum of resistance to multiple fungicides and contributing to the perpetuation of resis-
tant  strains in the environment. The emergence of fungicide-resistant isolates of human
pathogens has been related to the exposure to fungicides used in agroecosystems. Exam-
ples  include species of cosmopolitan occurrence, such as Fusarium and Aspergillus, which
cause diseases in both plants and humans. This review summarizes the information about
the  most important triazole fungicides that are largely used in human clinical therapy and
agriculture. We  aim to discuss the issues related to fungicide resistance and the recom-
mended strategies for preventing the emergence of triazole-resistant fungal populations
capable of spreading across environments.©  2016 Sociedade Bras
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Introduction
Fungicides are a key component in human therapy and
the control of plant diseases caused by fungi that threaten
human health and crop production.1–5 Among the several
types of fungicides, the azole group (triazole and imidazole
derivatives) was ﬁrst introduced in the 1970s.3 Since then,
azoles, especially the triazoles, have been widely used for
the control of fungal diseases of several plants and human
mycoses.6–8 As opposed to other systemic fungicides, the
speciﬁc site of action of triazoles is an inherent advan-
tage that has led to improved control efﬁcacy of the target
fungus.9,10 However, experience has shown that these com-
pounds are prone to resistance in the pathogenic population,
especially without the following of recommended practices
that are aimed at prolonging the effectiveness of these
fungicides.9,11,12
In this context, the efﬁcacy of triazole fungicides can be
affected due to cross-resistance or when an isolate devel-
ops resistance to all fungicides in a chemical group.13,14
Some authors have also suggested that cross- and multidrug-
resistance may be driving forces in the development of
resistance in fungi that are at the interfaces of agroecosys-
tem, domestic, and hospital environments.15,16 For instance,
emerging fungi in clinical environments include saprophytic
or plant pathogenic fungi that have previously exposed to tri-
azole fungicides and end up spreading into the environment
and infecting humans.6,17–19
In this mini review, we summarize key aspects of the triaz-
oles for therapeutic use and discuss the possible link between
triazole-resistant clinical isolates and the widespread use of
triazole fungicides for the control of fungal diseases, which
would have a major impact in agriculture.
Basic  aspects  and  therapeutic  use  of  triazoles
The azole fungicides are of synthetic origin and are char-
acterized by the presence of an aromatic ﬁve-membered
heterocycle. These include triazoles (two carbon atoms and
three nitrogen atoms), imidazoles (three carbon atoms and
two nitrogen atoms), and thiazoles (three carbon atoms, one
nitrogen atom and one sulfur atom).20 The characteristics of
the azole rings, which are distinguished by the number of
nitrogen and sulfur atoms, change the physical and chem-
ical properties, toxicity, and therapeutic efﬁcacies of these
compounds.21 Therefore, the addition of different substitutes
to the pristine 1,2,4-triazole molecule inﬂuences its fungicide
or fungistatic effect.
Triazoles affect the biosynthesis of ergosterol, a funda-
mental component of the fungal cell plasma membrane.22
The main target of antifungal azole drugs is lanosterol 14-
 demethylase (Erg11 protein), a cytochrome P450 enzyme
that is involved in the conversion of lanosterol to 4,4-
dimethylcholesta-8(9),14,24-trien-3-ol. The azole agents link
to this enzyme using the aromatic ﬁve-membered heterocycle
and thereby inhibit the cytochrome P450 catalytic activity.9,23
The absence of ergosterol and the increase of intermediate
compounds alter fungal membrane integrity as well as cell
morphology, which inhibits fungal growth.24,25 b i o l o g y 4 7 (2 0 1 6) 793–799
Triazoles are among the most common systemic fungicides
used in the control of plant diseases. Triazoles are absorbed
and translocated in the plant, where they act preventively
(before infection) or curatively (in the presence of symptoms)
by affecting germ tube and appressoria formation or hausto-
ria development and/or mycelial growth.26,27 By widening the
window of protection beyond protectant fungicides, which act
only preventatively and are not translocated, the advantages
of triazoles represent a breakthrough in increasing the produc-
tivity of various crops affected by fungal diseases.2 Around a
third of all fungicides used for the protection of crop yields
include triazoles, among which more  than 99% are inhibitors
of demethylation (DMI).28 However, triazole fungicides are also
known to present long-term stability, allowing them to remain
active in certain ecological niches, such as soil and water, for
several months.2,29
The number of antifungals available in the medical ﬁeld for
the treatment of systemic infections is relatively limited com-
pared to those used for controlling diseases in plants, which
is mainly due to problems related to erratic efﬁcacy, drug tox-
icity, and intrinsic resistance.30 These compounds are usually
effective in both topical and prophylactic treatments of inva-
sive fungal infections.31 However, new triazoles that are less
toxic to humans and with more  speciﬁc targets have been
investigated.32–34 The ﬁrst generation of triazoles for human
therapy included itraconazole and ﬂuconazole. The second
generation is represented by voriconazole and posaconazole,
which proved to be less toxic, safer, and with a broader spec-
trum of activity, including activity against fungi that were
resistant to the previous generation.35,36 Presently, isavucona-
zole, ravuconazole, and albaconazole are being investigated
in phase III clinical trials as extended-spectrum triazoles with
fungicidal activity against a wide number of clinically impor-
tant fungi.
Development  and  monitoring  of  triazole  resistance
The development of resistance to triazoles as a result of selec-
tive pressure by the continued use of regular or sub-regular
dosages of fungicide is typically quantitative and expressed by
a gradual change in the frequency of resistant isolates.10 The
main mechanisms involved have been reviewed and relate
to the overexpression of the CYP51 gene due to mutations
(insertions or duplications) in the promoter region and an
increase in molecular efﬂux by ABC transporters caused by the
overexpression of genes coding for membrane transport.9,37,38
Recently, a study that examined A. fumigatus isolates from
a range of clinical environments suggested point mutations
of CYP51 and TR34/L98H genomic regions in isolates obtained
from patients with long term use of triazole-based therapy for
the treatment of chronic aspergillosis.16
A key element in the sustainable use of fungicides is to
monitor the sensitivity of the pathogen population to a cer-
tain compound.39–41 There are a number of direct and indirect
methods recommended for speciﬁc fungi that are aimed at
estimating the EC50 (effective concentration at which 50% of
fungal growth is inhibited) and MIC (minimum inhibitory con-
centration) values.10,42–45
In the medical ﬁeld, the surveillance and prevention of
resistance to antifungal agents have been subject to many
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Table 1 – Pathogenic fungi with intrinsic or developed resistance to triazoles for human therapeutic use.
Triazole Fungi References
Itraconazole Aspergillus fumigatus;  Fusarium solani; F. oxysporum;  Zygomycetes; Candida spp. 83–87,63
Fluconazole Candida spp.; Saccharomyces cerevisiae;  Trichosporon spp.; Fusarium solani; F. oxysporum;
Scedosporium spp.; Penicillium spp.; Bipolaris australiensis; B. hawaiiensis;  B. spicifera;
Aspergillus spp.; Dermatophytes; Zygomycetes; dimorphic fungi; Cryptococcus neoformans
73,84,85,88–93
Voriconazole Aspergillus fumigatus;  Zygomycetes Trichosporon spp.; Penicillium spp. 86,87,94,95
Posaconazole Aspergillus fumigatus 96
Ravuconazole Fusarium solani; F.oxysporum; Zygomycetes; Pseudallescheria spp.; Scedosporium spp.;
Acremonium spp.; Sporothrix schenckii;  Scopulariopsis spp.; Paecilomyces spp.
20,34
Albaconazole Fusarium solani; Zygomycetes 34
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estrictive actions in recent years. More  speciﬁcally, the
DA (Food and Drug Administration) and the EMA (Euro-
ean Medicines Agency) regulate and approve the use of
ntimicrobials in North America and Europe, respectively.46
imultaneously, the Clinical and Laboratory Standards Insti-
ute (CLSI), together with the Subcommittee on Antifungal
usceptibility Testing (AFST) of the European Committee for
ntimicrobial Susceptibility Testing (EUCAST), publish in vitro
est protocols periodically for monitoring fungi sensibility to
ntifungal agents of clinical and veterinary use. These actions
llow for the standardization of parameters for the evaluation
f in vitro resistance in the laboratory. However, these actions
nd protocols do not involve the monitoring of resistance of
lant pathogenic fungi, thus challenging the use of antifungal
gents in clinical therapy.
In agriculture, the Fungicide Resistance Action Committee
FRAC), a technical group maintained by the industry, pro-
ides guidelines for the management of fungicide resistance,
uch as the need to estimate a baseline resistance level in iso-
ates sampled from the population prior to the commercial use
f a fungicide.47 During commercial use, reports of failures
n disease control and detection of resistant isolates (those
ith sensitivity levels lower than the baseline) are indicators
f the risk of developing fungicide resistance.47 Periodically,
nformation is provided by the FRAC about the risk of plant
athogens that ranges from low to high. Currently, many  stud-
es are known that report steadily increasing resistance to
riazoles in plant pathogenic fungi.48
riazole  resistance  in  clinical  isolates  and  agricultural  use
n the medical ﬁeld, the ﬁrst report of DMI’s resistance in
. fumigatus isolates dates back more  than three decades
go. However, the resistance to itraconazole by Aspergillus
pp. from the clinical environment was ﬁrst reported in
997 for three isolates obtained from California in the
ate 1980s.49 The prescription of triazoles as a preferential
hoice for the treatment of patients with respiratory dis-
ases has been considered to contribute to the development
f resistance to this group of fungicides.10,50,51 Multidrug-
esistance (MDR)52 is considered to be the cause of the
ailure of a wide range of antifungal agents available on
he market.53,54 As an emergent fungus in clinical envi-
onments, A. fumigatus holds a history of cross-resistance
nd multi-resistance to azoles.55 It is probable that millions
f people are not effectively treated due to infections by97
fungi exhibiting antifungal resistance, among which 4.8 mil-
lion cases are related only to the species of Aspergillus.56
The triazole antifungals commonly used in the medical
ﬁeld for the treatment of fungal diseases and pathogens
that have exhibited some level of resistance are listed in
Table 1.
It has been shown that exposure of environmental fungi
to triazole fungicides may cause shifts from susceptible to
resistant populations, especially in the absence of adaptive
costs which may facilitate the spread of resistant popula-
tions into diverse environments.57 The surge of “emerging
fungi” in the medical ﬁeld or fungi that are otherwise harmless
to humans, such as the zygomycetes and other hyaline ﬁla-
mentous fungi,2,57 has led some authors to hypothesize that
other mechanisms may be leading to resistance, such as the
large amount of fungicides used in agroecosystems.7,58,59 This
hypothesis was initially suggested by studies conducted in the
Netherlands13 and later corroborated by studies conducted
in Spain,60 Belgium,13 Norway,13 Great Britain,61 Denmark,62
France,63 China,64 Italy,65 Austria,65 and India.28
A few studies have jointly examined the sensitivity of
isolates that cause diseases in both plants and humans to
triazoles. These studies suggested that the selection of fungi-
cides with a similar mode of action as those used in human
drug therapy for triazole-resistant isolates could contribute
to the development of multi-resistant populations.66,67 The
development of cross-resistance to triazoles and the low num-
ber of triazoles recommended for human therapy relative to
the high number of triazoles used in agriculture may affect
triazole efﬁcacy for human therapy.6,10 For instance, the fun-
gus Colletotrichum graminicola that causes anthracnose of corn
plants is an emerging pathogen in humans. Resistance to
tebuconazole as well as to multiple other azole antifungals has
been reported in plant pathogenic populations used in clini-
cal medicine.68,69 Similarly, cross-resistance to triazoles was
observed in clinical isolates of Candida albicans and agricultural
environmental yeasts.70
Several other fungi have been found in association with
human and animal diseases, including species of several
genera such as Bipolaris, Macrophomina,  Aspergillus,  Fusa-
rium, Alternaria and Mucor18,71–73 (Table 2). The pathogenicity
of clinical isolates of the Fusarium solani species complex
was conﬁrmed in plants of the Cucurbitacea family, which
exhibited similar aggressiveness to isolates originating from
diseased plants.17 Criptococcus neoformans is also found in dif-
ferent environmental niches, such as plants and animals.74
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Table 2 – Main genera of fungi reported as the causative agents of diseases in plants and in humans.
Genus Species References
Fusarium F. dimerum;  F. verticilliodies; F. solani;  F. oxysporium;  F. gramminearum;  F. poae;  F.
sporotrichoides; F. culmorum
18,98,99
Alternaria A. alternate 100,101
Aspergillus A. ﬂavus; A. par
B. asiticus; A. terreus
18,98,102–104
Curvularia C. lunata 105
Cladosporium C. cladosporioides 106,107
Colletotrichum C. gloeosporioides,  C. coccodes 68,108
Mucor M. piriforms 109,110
Absidia Absidia spp. 18,109
Rhizopus R. arrizhus 109,111
cifera
rMacrophomina M. phaseolina
Bipolaris B. australiensis; B. hawaiiensis; B. spi
Fluconazole is the most prevalent clinical antifungal used to
treat cryptococcosis.75 However, the continued use of this anti-
fungal is an increasing concern due to the frequency of isolates
resistant to triazoles used in human therapeutic use.76 There
is a need for attention to azole resistance and optimal ther-
apy in regions with high incidence of cryptococcosis, such
as the Asian-Paciﬁc region (5.1–22.6%), Africa/Middle-East
(7.0–33.3%), and Europe (4.2–7.1%).77 In addition to ﬂuconazole
resistance in these regions, the new point of mutation in the
ERG11 gene of C. neoformans afforded resistance to voricona-
zole (VRC).78 In these cases, the spread of isolates exhibiting
resistance to triazoles into the environment and those capable
of causing human diseases may affect the efﬁcacy of therapeu-
tic control with fungicides of the same group, especially in the
presence of cross-resistance.79
The mutagenesis in TR34/L98H in azole-resistant Aspergillus
may have originated due to the use of triazole fungicides in
agroecosystems.14,28,80 Such mutation was detected in 89% of
A. fumigatus-resistant isolates from air samples, ﬂowers, and
soils from hospital areas.6 Microsatellite sequencing of clin-
ical and environmental isolates that lead to the TR34/L98H
mutation revealed high genetic homology, which suggests a
common ancestor.6,13
Future  directions
Triazole antifungals largely used in plant protection are also
important as antifungal treatments in the human medical
ﬁeld even though they possessing structural differences. How-
ever, sensitive populations that co-inhabit environments may
be reduced by the selection of isolates resistant to fungicides.
Fungi arising from agricultural ecosystems as opportunistic
pathogens may carry cross-resistance to triazoles used in the
medical ﬁeld. The restricted number of antifungal agents for
clinical use, which contrasts with the large number of agricul-
tural fungicides with similar modes of action, may be a risk
factor that limits the success of the therapeutic use of these
drugs.
Currently, genome-wide studies, together with novel T-
cell-based therapeutic approaches for the prophylaxis and
treatment of opportunistic fungal infections, have promising
avenues of research in the detection of potentially new anti-
fungal targets.81,82 Thus, different strategies should be the
main goals of the pharmaceutical industry.72
73,112
Given that the search for new antifungal drugs is a lengthy
process, the combination of drugs to achieve synergistic
effects is currently adopted as an alternative. This approach
includes the combination of drugs with distinct mechanisms
of action that may enhance efﬁcacy by combining low concen-
trations of both antifungal agents, thus diminishing the risk
of developing resistance.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
Acknowledgments
The authors are thankful to the Coordenac¸ão de
Aperfeic¸oamento de Pessoal de nível superior – CAPES
for ﬁnancial support. A.M. Fuentefria and H.S. Schrekker are
grateful to CNPq for the PQ fellowships.
 e  f  e  r  e  n  c  e  s
1. Horsfall JG. Fungi and fungicides. The story of a
nonconformist. Annu Rev Phytopathol.  1975;13:1–14.
2. Hof H. Critical annotations to the use of azole antifungals
for plant protection. Antimicrob Agents Chemother.
2001;45:2987–2990.
3. Russel PE. A century of fungicide evolution. J Agric Sci.
2005;143:11–25.
4. Dehne HW, Deising HB, Gisi U, Kuck KH, Russell PE, Lyr H.
Modern. Fungicides and antifungal compounds. In:
International Reinhardsbrunn Symposium Friedrichroda, Vol. 15.
2007:45–51.
5. Salam KP, Tomas JG, Beard C, Loughman R, Mac Leod WJ,
Salam MU. Application of meta-analysis in plant pathology:
a  case study examining the impact of fungicides on wheat
yield loss from the yellow spot-septoria nodorum blotch
disease complex in Western Australia. Food Secur.
2013;5:319–325.
6. Snelders E, Huis In’t Veld RA, Rijs AJ, Kema GH, Melchers
WJ, Verweij PE. Possible environmental origin of resistance
of Aspergillus fumigatus to medical triazoles. Appl Environ
Microbiol.  2009;75:4053–4057.
7. Brown GD, Denning DW, Levitz SM. Tackling human fungal
infections. Science. 2012;336:647.
r o b i b r a z i l i a n j o u r n a l o f m i c 
8. Cools HJ, Fraaije BA. Update on mechanisms of azole
resistance in Mycosphaerella graminicola and implications for
future control. Pest Manage Sci.  2013;69:150–155.
9. Ma Z, Michailides TJ. Advances in understanding molecular
mechanisms of fungicide resistance and molecular
detection of resistant genotypes in phytopathogenic fungi.
Crop Prot. 2005;24:853–863.
10. Deising HB, Reimann S, Pascholati SF. Mechanisms and
signiﬁcance of fungicide resistance. Braz J Microbiol.
2008;39:286–295.
11. McGrath MT. Fungicide resistance in cucurbit powdery
mildew: experiences and challenges. Plant Dis.
2001;85:237–245.
12. Denning DW, Park S, Lass-Florl C, et al. High-frequency
triazole resistance found in nonculturable Aspergillus
fumigatus from lungs of patients with chronic fungal
disease. Clin Infect Dis. 2011;52:1123–1129.
13. Snelders E, van der Lee HA, Kuijpers J, Rijs AJMM, Varga J.
Emergence of azole resistance in Aspergillus fumigatus and
spread of a single resistance mechanism. PLOS Med.
2008;5:1629–1637.
14. Snelders E, Camps SM, Karawajczyk A, et al. Triazole
fungicides can induce cross-resistance to medical triazoles
in  Aspergillus fumigatus. PLoS ONE. 2012;7:e31801.
15. Bowyer P, Denning DW. Environmental fungicides and
triazole resistance in Aspergillus. Pest Manage Sci.
2013;70:173–178.
16. Lelièvre L, Groh M, Angebault C, Maherault AC, Didier E,
Bougnoux ME. Azole resistant Aspergillus fumigatus: an
emerging problem. Med Mal Infect. 2013;43:139–145.
17. Mehl HL, Epstein L. Fusarium solani species complex isolates
conspeciﬁc with F. solani f. s: cucurbitae race 2 from naturally
infected human and plant tissue and environmental
sources are equally virulent on plants, grow at 37 ◦C and are
interfertile. Environ Microbiol. 2007;9:2189–2199.
18. De Lucca AJ. Harmful fungi in both Agriculture and
Medicine. Rev Iberoam Micol. 2007;24:3–13.
19. Kaur S, Dhillon GS, Brar SK, Vallad EG, Chand R, Chauhan
BV.  Emerging phytopathogen Macrophomina phaseolina:
biology, economic importance and current diagnostic
trends. Crit Rev Microbiol. 2012;38:136–151.
20. Catalán M, Montejo JC. Antifúngicos sistêmicos.
Farmacodinâmica Y Farmacocinética. Rev Iberoam Micol.
2006;23:39–49.
21. Sheppard D, Lampires HW. Agentes antifúngicos. In:
Katzung BG, ed. Farmacologia Básica e Cínica. Rio de Janeiro,
Brazil: McGraw Hill Interamericana do Brasil, Guanabara
Koogan; 2008:707–714.
22. Brent KJ. Fungicide Resistance in Crop Pathogens, How Can it be
Managed.  Brussels: Global Crop Protection Federation; 1995.
23. Becher R, Wirsel SGR. Fungal cytochrome P450 sterol
14-demethylase (CYP51) and azole resistance in plant and
human pathogens. Appl Microbiol Biotechnol. 2012;95:
825–840.
24. Becher R, Hettwer U, Karlovsky P, Deising HB, Wirsel SGR.
Adaptation of Fusarium graminearum to tebuconazole
yielded descendants diverging for levels of ﬁtness,
fungicide resistance, virulence, and mycotoxin production.
Phytopathology. 2010;100:444–453.
25. Serﬂing S, Ordon F. Virulence and toxin synthesis of an
azole insensitive Fusarium culmorum strain in wheat
cultivars with different levels of resistance to Fusarium
head blight (FHB). Plant Pathol. 2014;63:1230–1240.
26. Buchenauer H. Mechanism of action of triazolyl fungicides
and related compounds. In: Lyr H, ed. Modern Selective
Fungicides: Properties, Applications, Mechanisms of Action.
Harlow, United Kingdom: Longman Scientiﬁc and
Technical; 1987:205–231.o l o g y 4 7 (2 0 1 6) 793–799 797
27. Pontzen R, Scheinpﬂug H. Effects of triazole fungicides on
sterol biosynthesis during spore germination of Botrytis
cinerea,  Venturia inaequalis and Puccinia graminis f s: tritici.
Netherlands. J Plant Pathol. 1989;95:151–160.
28. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen
CH.  Isolation of multiple-triazole-resistant Aspergillus
fumigatus strains carrying the TR/L98H mutations in the
cyp51A gene in India. J Antimicrob Chemother.
2012;67:362–366.
29. Hamey PY, Harris CA. The variation of pesticide residues in
fruits and vegetables and the associated assessment of risk.
Regul Toxicol Pharmacol. 1999;30:34–41.
30. Bergold AM, Georgiadis S. Novidades em fármacos
antifúngicos: uma revisão new antifungic drugs: a review.
Visão Acad. 2004;5:159–172.
31. Hay R. Antifungal drugs. In: Katsambas A, Lotti T, eds.
European Handbook of Dermatological Treatments.  Berlin,
Germany: Springer; 2003:700–710.
32. Carrillo-Munõz AJ, Giusiano G, Ezcurra PA, Quindóz G.
Antifungal agents: mode of action yeast’s cell. Rev Esp
Quimioter.  2006;19:130–139.
33. Girmenia C. New generation azole antifungals in clinical
investigation. Expert Opin Investig Drugs. 2009;18:1279–1295.
34. Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole
antifungal drugs: focus on isavuconazole, ravuconazole and
albaconazole. Curr Opin Investig Drugs. 2010;11:165–174.
35. Thompson GR, Cadena J, Patterson TF. Overview of
antifungal agents. Clin Chest Med. 2009;30:203–215.
36. Vandeputte V, Ferrari S, Coste AT. Antifungal resistance and
new strategies to control fungal infections. Int J Microbiol.
2012;713687:1–26.
37. Coleman JJ, Mylonakis E. Efﬂux in fungi: la pièce de
résistance. PLoS ONE. 2009;5:1–7.
38. Ammar GA, Tryono R, Do K, Karlovsky P, Deising HB, Wirsel
SGR.  Identiﬁcation of ABC transporter genes of Fusarium
graminearum with roles in azole tolerance and/or virulence.
PLoS ONE. 2013;8:2–13.
39. Parnell S, van den Bosch F, Gilligan CA. Large-scale
fungicide spray heterogeneity and the regional spread of
resistant pathogen strains. Phytopathology. 2006;96:549–555.
40. Suzuki F, Yamaguchi J, Koba A, Nakajima T, Arai M. Changes
in  fungicide resistance frequency and population structure
of  Pyricularia oryzae after discontinuance of MBI-D
fungicides. Plant Dis. 2010;94:329–334.
41. Van der Heyden H, Dutilleul P, Brodeur L, Carisse O. Spatial
distribution of single nucleotide polymorphisms related to
fungicide resistance and implications for sampling.
Phytopathology.  2014;104:604–613.
42. Edgington LV, Khnw KL, Barron GL. Fungitoxic spectrum of
benzimidazole compounds. Phytopathology. 1971;61:42–44.
43. Liu X, Yin Y, Wu J, Jiang J, Ma Z. Identiﬁcation and
characterization of carbendazim-resistant isolates of
Gibberella zeae. Plant Dis. 2010;94:1137–1142.
44. Spolti P, Jorge BC, Del Ponte EM. Sensitivity of Fusarium
graminearum causing head blight of wheat in Brazil to
tebuconazole and metconazole fungicides. Trop Plant Pathol.
2012;37:419–423.
45. Spolti P, Del Ponte EM, Dong Y, Cummings JA, Bergstrom GC.
Triazole sensitivity in a contemporary population of
Fusarium graminearum from New York wheat and
competitiveness of a tebuconazole-resistant isolate. Plant
Dis.  2014;98:607–613.
46. Aparicio JF, Mendes MV, Antón N, Recio E, Martín JF.
Polyenemacrolide antiobiotic biosynthesis. Curr Med Chem.
2004;1:645–1656.47. Brent KJ, Hollomon DW. Fungicide resistance in crop
pathogens: how can it be managed? FRAC Monograph n.1.
2007.
 i c r o798  b r a z i l i a n j o u r n a l o f m
48. FRAC. FRAC cod list. FRAC information: list of resistance.
Available in: http://www.frac.brasil.org.br (accessed
05.05.15).
49. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ,
Manning PJ, Stevens DA. Itraconazole resistance in
Aspergillus fumigatus. Antimicrob Agents.  1997;41:1364–1368.
50. Shao PL, Huang LM, Hsueh PR. Recent advances and
challenges in the treatment of invasive fungal infections.
Int J Antimicrob Agents.  2007;6:487–495.
51. Gore RB. The utility of antifungal agents asthma. Curr Opin
Pulm Med. 2010;16:36–41.
52. Gulshan K, Moye-Rowley WS. Multidrug resistance in fungi.
Eukaryot Cell. 2007;6:1933–1942.
53. Fischbach MA, Walsh CT. Antibiotics for emerging
pathogens. Science.  2009;325:1089–1093.
54. Pfaller MA, Diekema DJ. Progress in antifungal
susceptibility testing of Candida sp.: by use of clinical and
laboratory standards institute broth microdilution
methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–2856.
55. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin
DS. Multi-azole resistance in Aspergillus fumigatus. Int J
Antimicrob Agents. 2006;28:450–453.
56. Denning D, Pleuvry A, Cole D. Global burden of ABPA in
adults with asthma and its complication chronic
pulmonary aspergillosis in adults. Med Mycol.
2013;51:361–370.
57. Verweij E, Kema GH, Zwaan B, Melchers WJ. Triazole
fungicides and the selection of resistance to medical
triazoles in the opportunistic mould Aspergillus fumigatus.
Pest Manage Sci.  2013;69:165–170.
58. Ruping MJGT, Vehreschil JJ, Cornely OA. Patients at high risk
of invasive fungal infections: when and how to treat. Drugs.
2008;68:1941–1962.
59. Tobudic S, Kratzer C, Presterl E. Azole-resistant Candida sp.:
emerging pathogens. Mycoses. 2012;55:24–32.
60. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E,
Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M.
Epidemiological cutoffs and cross-resistance to azole drugs
in  Aspergillus fumigates. Antimicrob Agents Chemother.
2008;52:2468–2472.
61. Howard SJ, Pasqualotto AC, Denning DW. Azole resistance
in allergic bronchopulmonary aspergillosis and Aspergillus
bronchitis. Clin Microbiol Infect. 2010;16:683–688.
62. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL,
Johansen HK. Environmental study of azole-resistant
Aspergillus fumigatus and other aspergilli in Austria,
Denmark, and Spain. Antimicrob Agents Chemother.
2010;54:4545–4549.
63. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron
J,  Kanaan R. High prevalence of azole-resistant Aspergillus
fumigatus in adults with cystic ﬁbrosis exposed to
itraconazole. Antimicrob Agents Chemother. 2012;56:869–874.
64. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ,
Balajee SA. Azole resistance in Aspergillus fumigatus isolates
from the ARTEMIS global surveillance study is primarily
due to the TR/L98H mutation in the cyp51A gene. Antimicrob
Agents Chemother. 2011;55:4465–4468.
65. Van der Linden JW, Arendrup MC, Verweij PE.
SCARE-Network. Prospective International Surveillance of Azole
Resistance in Aspergillus fumigatus (SCARE-Network). Chicago,
USA: ICAAC; 2011.
66. Meneau I, Sanglard D. Azole and fungicide resistance in
clinical and environmental Aspergillus fumigatus isolates.
Med Mycol. 2005;43:307–311.
67. Drummond DE, Reimão JQ, Dias ALT, Siqueira AM.
Comportamento de mostras ambientais e clínicas de
Cryptococcus neoformans frente a fungicidas de uso
agronômico e ao ﬂuconazol. Rev Soc Bras Med Trop.
2007;2:209–211. b i o l o g y 4 7 (2 0 1 6) 793–799
68. O’Quinn RP, Hoffman JL, Boyd AS. Colletotrichum species as
emerging opportunistic fungal pathogens: a report of 3
cases of phaeohyphomycosis and review. J Am Acad
Dermatol.  2001;l45:56–61.
69. Serﬂing A, Wohlrab J, Deising HB. Treatment of a clinically
relevant plant pathogenic fungus with an agricultural azole
causes cross-resistance to medical azoles and potentiates
caspofungin efﬁcacy. Antimicrob Agents Chemother.
2007;51:3672–3676.
70. Müller FM, Staudigel A, Salvenmoser S, Tredup A,
Miltenberger R, Herrmann JV. Cross-resistance to medical
and agricultural azole drugs in yeasts from the oropharynx
of  human immunodeﬁciency virus patients and from
environmental Bavarian vine grapes. Antimicrob Agents
Chemother. 2007;51:3014–3016.
71. Mehanna HM, Kuo T, Chaplin J, Taylor G, Morton RP. Fungal
laryngitis in immunocompetent patients. J Laryngol Otol.
2004;118:379–381.
72. Srinivasan A, Wickes BL, Romanelli AM, Debelenko L,
Rubnitz JE. Cutaneous Infection caused by Macrophomina
phaseolina in a child with acute myeloid leukemia. J Clin
Microbiol.  2009;47:1969–1972.
73. Cunha KC, Sutton DA, Fothergill AW, et al. Diversity of
Bipolaris species in clinical samples in the United States and
their antifungal susceptibility proﬁles. J Clin Microbiol.
2012;50:4061–4066.
74. Chowdhary A, Randhawa HS, Sundar G, et al. In vitro
antifungal susceptibility proﬁles and genotypes of 308
clinical and environmental isolates of Cryptococcus
neoformans var. grubii and Cryptococcus gattii serotype B from
north-western India. J Med Microbiol. 2011;60:961–967.
75. Gullo FP, Rossi SA, Sardi Jde C, Teodoro VL,
Mendes-Giannini MJ, Fusco-Almeida AM.  Cryptococcosis:
epidemiology, fungal resistance, and new alternatives for
treatment. Eur J Clin Microbiol Infect Dis.  2013;32:1377–1391.
76. Paul S, Doering TL, Moye-Rowley WS. Cryptococcus
neoformans Yap1 is required for normal ﬂuconazole and
oxidative stress resistance. Fungal Genet Biol.  2015;74:
1–9.
77. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the
ARTEMIS DISK Global Antifungal Surveillance Study, 1997
to  2007: 10-year analysis of susceptibilities of noncandidal
yeast species to ﬂuconazole and voriconazole determined
by  CLSI standardized disk diffusion testing. J Clin Microbiol.
2009;47:117–123.
78. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. Cryptococcus
neoformans overcomes stress of azole drugs by formation of
disomy in speciﬁc multiple chromosomes. PLoS Pathog.
2010;6:1–13.
79. Williams DA, Lemke TL. Foye’s Principles of Medicinal
Chemistry.  5a ed. New Jersey, USA: Philadelphia, Lippincot
Williams and Wilkins; 2002.
80. Singh PK, Gaur SN, Hagen F, et al. Possible environmental
origin of resistance of Aspergillus fumigatus to medical
triazoles. Appl Environ Microbiol. 2009;75:4053–4057.
81. Barrera A, Alastruey-Izquierdo A, Martín MJ, Cuesta I,
Vizcaíno JA. Analysis of the protein domain and domain
architecture content in fungi and its application in the
search of new antifungal targets. PLoS Comput Biol.
2014;10:1–16.
82. Mancini N, Marrone L, Clementi N, Sautto GA, Clementi M,
Burioni R. Adoptive T-cell therapy in the treatment of viral
and opportunistic fungal infections. Future Microbiol.
2015;10:665–682.
83. Alastruey-Izquierdo A, Cuenca-Estrella M,  Monzón, Emilia
Mellado A, Rodríguez-Tudela JL. Antifungal susceptibility
proﬁle of clinical Fusarium spp. isolates identiﬁed by
molecular methods. J Antimicrob Chemother. 2008;61:
805–809.
r o b i b r a z i l i a n j o u r n a l o f m i c 
84. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC.
Frequency and evolution of azole resistance in Aspergillus
fumigatus associated with treatment failure. Emerg Infect Dis.
2009;15:1068–1076.
85. Almeida LMM, Souza EAF, Bianchin DB, Svidzinski TIE.
Resposta in vitro de fungos agentes de micoses cutâneas
frente aos antifúngicos sistêmicos mais utilizados na
dermatologia. An Bras Dermatol. 2009;84:249–255.
86. Beernaert LA, Pasmans F, Van Waeyenberghe L, et al. Avian
Aspergillus fumigatus strains resistant to both itraconazole
and voriconazole. Antimicrob Agents Chemother.
2009;53:2199–2201.
87. Dota KFD, Freitas AR, Consolaro MEL, Svidzinski TIE. A
challenge for clinical laboratories: detection of antifungal
resistance in Candida species causing vulvovaginal
candidiasis. Lab Med. 2011;42:87–93.
88. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda
G. Mechanisms of azole resistance in clinical isolates of
Candida glabrata collected during a hospital survey of
antifungal resistance. Antimicrob Agents Chemother.
2015;49:668–679.
89. Quintero CHG. Resistencia de levaduras del género Candida
al  ﬂuconazol Candida yeast’s resistance to ﬂuconazol.
Infectio.  2010;14:172–180.
90. Cheong JW,  McCormack J. Fluconazole resistance in
cryptococcal disease: emerging or intrinsic. Med Mycol.
2013;51:261–269.
91. Adimi P, Hashemi SJ, Mahmoudi M, et al. In-vitro activity of
10  antifungal agents against 320 dermatophyte strains
using microdilution method in Tehran. IJPR.
2013;12:537–545.
92. Wang JF, Xue Y, Zhu XB, Fan H. Efﬁcacy and safety of
echinocandins versus triazoles for the prophylaxis and
treatment of fungal infections: a meta-analysis of RCTs. Eur
J  Clin Microbiol Infect Dis. 2015;34:651–659.
93. Hashemi SM, Badali H, Faramarzi MA, et al. Novel triazole
alcohol antifungals derived from ﬂuconazole: design,
synthesis, and biological activity. Mol Divers. 2015;19:15–27.
94. Van der Linden JW, Jansen RR, Bresters D, et al.
Azole-resistant central nervous system aspergillosis. Clin
Infect Dis. 2009;48:1111–1113.
95. Chowdhary A, Kathuria S, Agarwal K, et al.
Voriconazole-resistant Penicillium oxalicum: an emerging
pathogen in immunocompromised hosts. Open Forum Infect
Dis.  2014;1:1–7.
96. Choukri F, Botterel F, Sitterlé E, et al. Prospective evaluation
of azole resistance in Aspergillus fumigatus clinical isolates
in France. Med Mycol. 2015;53:593–596.
97. Gregson L, Goodwin J, Johnson A, et al. In vitro susceptibility
of Aspergillus fumigatus to isavuconazole: correlation witho l o g y 4 7 (2 0 1 6) 793–799 799
itraconazole, voriconazole, and posaconazole. Antimicrob
Agents Chemother. 2013;57:5778–5780.
98. Naiker S, Odhav B. Mycotic keratitis: proﬁle of Fusarium
species and their mycotoxins. Mycoses. 2004;47:50–56.
99. Mehl HL, Epstein L. Sewage and community shower drains
are environmental reservoirs of Fusarium solani species
complex group 1, a human and plant pathogen. Environ
Microbiol.  2008;10:219–227.
100. Brandt ME, Warnock DW. Epidemiology, clinical
manifestations, and therapy of infections caused by
dematiaceous fungi. J Chemother. 2003;2:36–47.
101. Chhabra V, Rastogi S, Barua M, Kumar S. Alternaria
alternata infection associated osteomyelitis of maxilla: a
rare  disease entity. Indian J Dent Res.  2013;24:639–641.
102. Diener UL, Cole RJ, Sanders TH, Payne GA, Lee LS, Klich MA.
Epidemiology of aﬂatoxin formation by Aspergillus ﬂavus.
Annu Rev Phytopathol. 1987;25:249–270.
103. Abbas HK, Williams WP,  Windham GL, Pringle CH, Xie W,
Shier WT. Aﬂatoxin and fumonisin contamination of
commercial corn (Zea mays) hybrids in Mississippi. J Agric
Food  Chem. 2002;50:5246–5254.
104. Lass-Florl C, Mayr A, Perkhofer S, et al. Activities of
antifungal agents against yeasts and ﬁlamentous fungi:
assessment according to the methodology of the European
Committee on Antimicrobial Susceptibility Testing.
Antimicrob Agents Chemother. 2008;52:3637–3641.
105. Navi SS, Bandyopadhyay R, Reddy RK, Thakur RP, Yang XB.
Effects of wetness duration and grain development stages
on sorghum grain mold infection. Plant Dis.  2005;89:872–878.
106. Tournas VH. Spoliage of the vegetable crops by bacteria and
fungi and related health hazards. Crit Rev Microbiol.
2005;31:33–44.
107. Weikl F, Radl V, Munch JC, Pritsch K. Targeting allergenic
fungi in agricultural environments aids the identiﬁcation of
major sources and potential risks for human health. Sci
Total Environ.  2015;25:223–230.
108. Cano J, Guarro J, Molecular Gené J. Morphological
identiﬁcation of Colletotrichum species of clinical interest. J
Clin Microbiol. 2004;42:2450–2454.
109. Kobayashi M, Hiruma M, Matsushita A, Kawai M,  Ogawa H,
Udagawa S. Cutaneous zygomycosis: a case report and
review of Japanese reports. Mycoses. 2001;44:311–315.
110. Miceli MH, Lee SA. Emerging moulds: epidemiological
trends and antifungal resistance. Mycoses. 2011;54:666–678.
111. Cornely OA. Aspergillus to Zygomycetes: causes, risk
factors, prevention, and treatment of invasive fungal
infections. Infection. 2008;6:296–313.
112. El Khizzi N, Bakheshwain S, Bipolaris Parvez S. A plant
pathogen causing human infections: an emerging problem
in  Saudi Arabia. Res J Microbiol. 2010;5:212–217.
